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Prospects of Clinical Xenotransplantation 
T.E. Starzl. A. Tzakis. J.J. Fung, S. Todo. A.J. Demetris. A. Manez, I.A. Marino. L. Valdivia. and N. Murase 
OUR two recent atte~pts ~t baboon-to-human xe-
notransplantatton faJled. I -. However. there were 
encouraging notations. First. the xenografts had no evi-
dence of B virus infection during their posttransplant 
survival of 70 and 26 days in B virus carriers. Second. 
there also was little histopathologic evidence of humoral or 
cellular rejection of these livers. Yet. their function was 
suboptimal. If rejection was not the explanation. why did 
the baboon liver cases fail? 
WERE THE OPERATIONS FLAWED? 
The surgical techniques were adapted from hepatic allo-
transplantation. 4 Although the baboon donors were large. 
their body weights were only 40% of the recipients. 
necessitating the so-called piggyback operation that leaves 
the recipient vena cava intact (Fig I). This procedure. 
which was first described by Calne and tilliam~ in 1968 
and later popularized by Tzakis et al.o requires more skill 
to perform than the standard operation. In our opinion. it 
is increasingly dangerous in proportion to the donor/ 
recipient size disparity. Of course. this means that the 
Fig 1. Piggyback operation used for both baboon-to-human 
xenotransplantations. CA. celiac axiS: CHA. common hepatic 
artery: PV. portal vein. 
Fig 2. Extent of regeneration of the baboon liver from ItS onginal 
size (silhouette to the size displayed by the CAT scan after 12 
days). 
baboon is not an ideal donor-even from a purely technical 
point of view-for adult humans. 
Nevertheless. the procedures were initially satisfactory. 
Once the livers were in. they regenerated up to optimal 
volume for recipient size in both cases. The silhouette in 
Fig 2 is the original baboon liver size laid over the actual 
computed axial tomographic (CAT) scan at 12 days in 
patient I. On this day. the liver appeared grossly normal at 
surgical re-exploration and biopsy. Histopathologically. 
the bromodeoxyuridine (BrDU) monoclonal antibody with 
which the biopsy sections were stained showed multitudes 
of brown-stained (proliferating) hepatocytes and duct 
cells. There were almost no infiltrating immunocytes. 
COMPARISON OF RECIPIENTS 
The conventional lymphocytotoxic crossmatch of the re-
cipient sera with their donor lymphocytes was positive 
initially but negative after dithiothreitol mIT) treatment 
(Table I). meaning that the antibodies were largely IgM. 
The conventional crossmatches became negative postop-
eratively. Both patients had ABO compatible donors: A to 
A in case I and B to B in case 2. They were equivalently 
immune competent with in vitro testing. Estimated sur-
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Table 1. Similarities 
Case 1 Case 2 
Lymphocytotoxic crossmatch 
Crossmatdl after OTT 
Crossmatdl postoperation 
ABO 
Prognosas without transplantation 









vival time without transplantation was less than I month in 
both cases. 
These were the similarities. One difference that may 
have been important was that patient 1 had asymptomatic 
human immunodeficiency virus (HIV; Table 2). In addi-
tion. he had undergone splenectomy 3 years previously 
following a motorcycle accident. whereas patient 2 did not 
have splenectomy until the fourth postoperative day. An-
other difference was that patient I was half the age of 
patient 2 and far less frail. The day before the operation. 
patient 2 developed deep hepatic coma and was placed on 
a ventilator. 
POSTOPERATIVE CLINICAL COURSES 
Case 1 
Patient I awoke promptly from anesthesia and resumed 
diet and ambulation. Although he became jaundice free for 
most of the 70 days of survival. the canalicular enzymes 
were high from the second week onward; alkaline phos-
phatase levels rose to over 10.000 IV. Serum transami-
nases were only modestly elevated perioperatively, or for 
that matter at any -subsequent time.2 
When icterus finally developed 2 months after transplan-
tation. it was ascribed to partial obstruction of the recon-
structed bile duct. even though the biliary-enteric anasto-
mosis appeared satisfactory by cholangiography (Fig 3). At 
autopsy at 70 days. the entire biliary tree was tilled with 
inspissated bile. and most of the biliary ducts. which by 
this time had become bile lakes. were denuded of epithe-
lium (Fig 4). This can be the end result with unrelieved 
obstruction. but the alternative explanation could have 
been that the epithelial damage was the primary. not a 
derivative. event. 
Case 2 
In contrast to the first one. this patient remained icteric 
and comatose postoperatively. J The xenograft had the 















Fig 3. Transhepatic cholangiogram that was read at nonnal after 
2 months in patient 1 . The choledochojejunostomy anastomosis is 
marked with an arrow. 
despite an unquestionably adequate biliary anastomosis. 
This patient's lowest bilirubin was !l mgldL on the fourth 
postoperative day, down from 17.3 mgldL. but increasing 
thereafter to the terminal concentration of 28.3 mgldL. As 
in the first patient. the jaundice was not particularly 
responsive to steroid boluses and increased maintenance 
doses of prednisone. 
METABOLIC INCOMPATIBILITY 
Having the same problem twice with cholestasis raised the 
possibility that the baboon liver produced a lithogenic bile 
in the human environment. This has not been absolutely 
ruled out. but we doubt it. Equally perplexing in both 
patients was the inability of the baboon livers to maintain 
the postoperative serum albumin above 2 gldL in spite of 
other adequate synthetic function induding prothrombin 
time. ~Kg These seemingly healthy baboons had been ac-
cepted as donor cases because of (heir large size. even 
(hough they were both more than 15 years old and had 
hypoalbuminemia. This was not a "normal" finding as was 
(hought at the time. In a recent study of 25 ostensibly 
healthy haboons housed at (he Southwest Foundation 
1084 
Fig 4. Inspissated bile in the xenograft of patient 1 after 70 days. 
The black material in the ducts is the inspissated bile and the black 
spots in the liver parenchyma are bile lakes. 
from which our donors came. the mean serum albumin was 
3.5 = 0.7 SD gmldL (range 1.8 to 5.1). not suggesting a 
genetically determined limit on albumin production. 7 Sim-
ilar results from a different baboon colony at Ohio State 
were recently reported. M 
CAUSES OF DEATH 
A ruptured mycotic intracerebral aneurysm (caused by 
aspergillus) was the immediate cause in case 1. 2 In case 2. 
peritonitis was listed as the official cause of death. second-
ary to an anastomotic leak at the jejunojejunostomy of the 
Roux-en-Y biliary reconstruction. 3 However. both pa-
tients developed renal failure and in fact patient 2 never 
made a drop of urine postoperativel y. The most disquieting 
fact was that neither hepatic xenograft provided adequate 
function. The mystery was the disparity between the 
paucity of the histopathologic abnormalities (which was 
very encouraging) and the discouraging (and unexplained) 
functional deficiencies of these transplants. which sug-
gested incomplete control of xenograft rejection. 
CONTROL OF REJECTION 
Previous Historical Expenence 
Nearly 30 years ago. six baboon kidney xenografts were 
transplanted to patients treated with azathioprine-pred-
nisone immunosuppression. The organs functioned for 6 to 
60 days.9 At the end. the baboon kidney xenografts had 
fierce cellular rejection. However. the key finding was a 
presumably antibody-mediated (humoral) occlusive endo-
thelialitis of the graft vessels that closed off much of the 
arterial supply. The consequent distal ischemia appeared 
to be responsible for patchy gangrene of the xenografts. 
interspersed between islands of still functional paren-
chyma. Similar gross and histopathologic findings were 
reported more than 20 years later by Bailey et altO after 
cardiac xenotransplantation under a cyclosporine (ey A)-
based immunosuppressive regimen (the Baby Fae case). 
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Liver Xenografts 
A four-drug immunosuppressive cocktail was used. This 
consisted of FK 506 given IV or orally. prednisone. 
prostaglandin E,. and cyclophosphamide. The cyclophos-
phamide. like the other three drugs. was started IV and 
continued orally in doses that were not myelotoxic as 
judged by normal white blood cell count. ~KP The striking 
value of cyclophosphamide and other antimetabolites 
when used in combination with FK 506 had been demon-
strated in hamster-to-rat heart and liver transplantation by 
Murase et alii and in the same heart model with ey A by 
Hasan et al. 12 In her rat liver xenograft recipients. Murase 
demonstrated the cell migration and systemic microchi-
merism. I which we believe is associated with and neces-
sary for both allograft or xenograft acceptance. and is the 
first stage of tolerance inductionKfg-f~ Valdivia et alit. 
showed that the hamster liver graft itself.becomes a genetic 
composite. in the same way as allografts do. In our 
patients. striking chimerism also was evident. 2.3 Baboon 
DNA was found by polymerase chain reaction (peR) in 
essentially all tissues retrieved at autopsy at 70 days from 
patient I. In addition to the liver. patient 2 was given a 
large dose of un purged bone marrow cells (3 x 10M/kg body 
weight) perioperatively. He also had mixed xenogeneic 
chimerism at all times until death. 
Cellular Rejection. Only one of the seven biopsies ob-
tained from patient 1 (this was on day 12) had a mild focal 
cellular rejection by the conventional criteria used for 
hepatic allografts. On day 64 there was a mild but diffuse 
increase in T (CD3+) and NK (Leu-7+) cells in the 
sinusoids and septal bile ducts of patient I but the findings 
were insufficient for an unequivocal diagnosis of rejection. 
There was some centrilobular hepatocyte drop out. This 
was the worst looking biopsy in either case by criteria of 
cellular rejection. 
No definite evidence of cellular rejection was seen in 
any of the seven biopsy samples taken from patient 2 over 
a 26-day period. 
Vascular Rejection. The xenograft of both patients out 
to 70 and 26 postoperative days was entirely free of the 
arteritis that has been associated with vascular rejection in 
all previous baboon-to-human kidney or heart grafts. Nev-
ertheless. sludging as well as the presence of polymorpho-
nuclear leukocytes was seen in the sinusoids of the xe-
nografts immediately after reperfusion. compatible with 
the diagnosis of an aborted hyperacute rejection. 
COMPLEMENT ACTIVATION INJURY 
Total complement was depleted for most of the critical first 
2 weeks whereas complement components e3. 4. and 5 
became undetectable. During this time. circulating im-
mune complexes appeared (Table 3). After 10 days. the 
complement system settled down but irreversible damage 
may have been done.) This complement evolution was 
very similar to that reponed in Paris last year by Manez et 
CLINICAL XENOTRANSPLANTATION 
Table 3. Total Serum Hemolytic Complement (CH100), 
Complement Components (U/mL), and Immune Complexes (Ie) 
Days CH100 C3 C4 C5 
posloperallVe (>60) (83-177) (15-45) (6-20) Ie 
Pretransptant <21 35 7 + 
1 <21 33 3 + 
3 <21 27 3 + 
5 <21 27 5 + 
7 <21 33 6 + 
9 <21 40 8 
11 21 29 6 
14 43 
17 55 64 17 20 
23 66 59 15 17 
26 61 51 15 11 + (low) 
28 44 40 13 14 
33 55 58 14 15 + (low) 
64 55 
al 17 in recipients of allografts transplanted across a positive 
lymphocytotoxic crossmatch. 
Although these baboon liver xenografts had little evi-
dence of cellular or vascular rejection. they exhibited a 
very fine microsteatosis on their first biopsies that became 
obvious within a few days. particularly in case 2 (Fig 5). 
This finding has been reponed in cases of allotransplanta-
tion with inexplicable primary hepatic nonfunction. Al-
though these findings receded. the microsteatosis may 
have been a sublethal injury that precluded long-term 
success in either case. 
During this early phase. there was binding of IgM and 
IgO in the grafts. In both patients. the immunoglobulins 
largely disappearecifrom the graft tissues except for [gO, 
which was positive- throughout. 
Relation to Hyperacute Allograft RejectIOn 
We believe that these livers were acutely damaged by an 
incomplete version of a form of rejection that we described 
Fig 5. ExtenSive mlcrosteatoslS In a liver biopsy obtaIned from 
pauent 2 after 4 days. Although thIS liver had acceptable synthetIC 
functIon except for albumIn. it dId not clear Jaundice. H&E.'- 200. 
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in 1964 in ABO-incompatible kidneys l8 and with Terasaki 
et al 19 a year later in kidney allografts transplanted across 
a positive Iymphocytotoxic crossmatch. These were the 
first ever descriptions of hyperacute kidney rejection as-
sociated with preformed antigraft antibodies. They were 
followed in 1966 by Kissmeyer-Neilsen et al's reponK~o 
The mind set created by these three papers that hyperacute 
rejection always is precipitated by antigraft antibodies 
quickly became one of the sacred cows of transplantation 
immunology. 
Several years later joined by Frank J. Dixon of the 
Scripps Institute (La Jolla) in a revolt against the sacred 
cow, we defined hyperacute kidney rejection as a comple-
ment activation syndrome with mechanisms analogous to 
the Shwartzman and local Anhus reactions.21 •22 We 
pointed out that although hyperacute allograft rejection 
usually was associated with antigraft antibodies. this was 
not an absolute requirement. It was a heretical statement 
at the time. 
However. the distinction we had made between hyper-
acute rejection with and without preformed antibodies was 
merely the dilference between the classical pathway of 
complement activation in which the first steps are antibody 
dependent vs the alternative pathway that does not require 
an antibody trigger or the panicipation of complement 
components Ct. 2. and 4. It always has seemed to us that 
these hyperacute allograft rejection syndromes with or 
without preformed antigraft antibodies are not fundamen-
tally dilferent than those seen after xenotransplantation of 
organs between genetically diverse species. 1.23 
PHARMACOLOGIC CONTROL OF 
COMPLEMENT ACTIVATION 
The complement pathogenicity is derived from the cleav-
age products of C3 and CS. The harmful consequences 
have been etfectively mitigated (but not eliminated) with 
cobra venom (which depletes C3 and CS) and soluble 
recombinant complement receptor type I that binds to the 
cleavage fragments of C3 and CS preventing amplification 
through C3b. However. binding to the anaphylatoxins C3a 
and C5a prevents another mechanism of complement 
injury-namely activation of mast cells. polymorphonu-
clear leukocytes. and other sources of soluble inflamma-
tory mediators such as platelet activating factor.;U5 Thus. 
cobra venom and the soluble complement receptor I 
impede by dilferent mechanisms both the classical and 
alternative cascades. By shutting olf both pathways. such 
agents could interdict or ameliorate the Anhus reaction. 
Shwartzman reaction. and neutrophil-mediated tissue in-
jury. 
Perhaps the most interesting anticomplement drug is a 
sesquiterpene compound called K76. which is produced by 
a specIes of fungi imperfectl found in the soil of one of the 
Okinawa islands. This drug blocks the C5 step of comple-
ment activation and also acceler.ltes the decay of CSb. just 
rroximal to the formation of the membmne attack complex 
I MAC) formed by complement components 5 to') in both 
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Fig 6. Classical and altemative complement activation pathways 
with the site of interdiction of these cascades by the experimental 
drug K76. 
the classical and alternative pathways of complement 
activation (Fig 6). Our attention was drawn to K76 by the 
article by Miyagawa et al26 in the April 1993 issue of 
Transplantation. which actually was a negative report. 
Intraperitoneal K76 was described as having no effect on 
the hyperacute rejection of guinea pig hearts transplanted 
to rats (Fig 7). Another drug called FUT (a synthetic 
inhibitor of serine protease) had a small therapeutic effect 
by itself (third and fourth bars. Fig 7). K76 and FUT 
together allowed heart graft survival for 100 minutes (fifth 
bar. Fig 7). 
Realizing that the results of the second and fifth groups 
could be internally inconsistent. we obtained a small 
supply of K76. When Murase et alII gave the same dose 
(200 mg/kg) of K76 to rats. but IV instead of intraperito-
neally. median survival of guinea pig hearts in rats was 
increased by a single dose from 8 minutes to more than 8 
hours. and in one experiment to more than a day. The 
astonishing potency of IV K76 by itself. or in combination 
with the other drug FUT. has also been shown in the very 
difficult pig-to-dog kidney xenograft model-with func-
tioning graft survival out to 8 hours during which 200 mUh 
of urine was produced. This is a truly extraordinary 
achievement. with this most difficult of all large animal 
models. 
Of course. control of the complement pathogenicity for 
a few hours with a drug like K76 does not mean anything 
per se. However. this could be the missing piece in a 
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Fig 7. Results reported by Miyagawa et al.26 which appeared to 
show no effect of K76 alone on guinea pig-to-rat heart transplan-
tation. The serine protease inhibitor. FUT. allowed minor prolon-
gation of heartbeat in this study. which was greatly enhanced by 
combining FUT with K76. 
treatment recipe for clinical use. In this context. the 
anticomplement drug is envisioned only as an adjunct to 
the drug cocktail already shown to be highly effective in 
our clinical cases but deficient in that it did not deal with 
the very earliest mechanism of complement injury. Exper-
iments to verify this hypothesis with various cocktail 
regimens are underway in our laboratory by Murase. 
Todo. Tzakis. and others in several small and large animal 
models. 
Complement Change After Liver Transplantation 
The need to prevent complement activation may be short 
term. particularly if the transplantation is of the liver. 
which is the principal source of the body's complement 
and the sole source of most complement components such 
as C3. In this connection. a paper by Valdivia et al 27 at this 
meeting has tremendous potential importance because it 
shows the species restriction of complement. 
In their investigation. the combination of hamster liver 
and its complement plus the rat recipient equaled a rat 
swimming in hamster complement (Fig 8). They showed 
how in the new complement environment. hyperacute 
rejection of stable liver and heart xenografts could be 
precipitated with just 1 mL of IV antihamster rat serum 
(Fig 9). This was a specific effect of the rat complement 
rather than the rat anti-hamster antibody infused into the 
rat recipient. The hyperacute rejection could be com-
pletely avoided by simply heating the rat serum at 56°C for 
30 minutes (Fig 9). which allowed retention of the rat 
anti-hamster antibodies but removed the rat complement. 
The demonstration of species restriction of complement is 
a fundamental discovery that undoubtedly will be ex-
ploited to facilitate xenograft acceptance. 
This mechanism might explain the terminal course of 
our second recipient. This patient had a normal liver 
CLINICAL XENOTRANSPLANTATION 
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Fig 8. Demonstration by Valdivia et al27 that the complement 
environment of a xenograft recipient becomes that of the donor 
species. See text for explanation. 
biopsy on days 24 and 25 when he was explored for an 
enteric fistula-yet less than I day later. the graft was 
found to be necrotic. What had happened? One possible 
explanation came from the possibility that human blood 
Fig 9. Experiment of Valdivia et a1 2 ' showing species restriction 
of complement. See text for explanation. 
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and blood products infused during these emergency oper-
ations contained human complement and anti-baboon an-
tibodies. It requires no imagination to suggest that we 
might have accidentally performed Valdivia et al'sZ7 ex-
periment in the operating room. The need to control the 
complement that is given to liver xenograft recipients will 
never again be very far from our minds. 1 have been told by 
our blood bankers that preparing complement-free blood 
constituents will be quite feasible. 
CONCLUSIONS 
This presentation is too complex for easy summarization. 
However. the impression I want to leave is that the 
xenograft barrier may be more vulnerable than most 
people realize at present. More than ever, cracking the 
complement shell that prohibits the exploitation of what 
hides inside via the classical or alternative pathway does 
not seem unrealistic. Once entry is achieved, it is clear that 
conventional cellular and vascular rejection can be con-
trolled with modem drug combinations. The complement 
reactions are the same as those that can abruptly destroy 
allografts. Now. the prospect of dealing with these prob-
lems and subsequent classical rejection with very straight-
forward strategies seems closer than ever. An additional 
possibility is the production of transgenic animals whose 
organs have complement regulatory proteins (such as 
decay accelerating factor [OAF] and C059). 
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